Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) is a clinical-stage biotechnology company pioneering small molecule therapies for hematologic disorders, cancer, and immune diseases. This news hub provides investors and healthcare professionals with rigorously verified updates on RIGL's clinical developments, regulatory milestones, and strategic partnerships.
Key resources include earnings announcements, trial result disclosures, FDA submissions, and licensing agreements. Our curated collection enables stakeholders to track the progress of oral kinase inhibitors and novel therapeutic candidates through development pipelines.
Bookmark this page for centralized access to Rigel's latest scientific advancements and business updates. All content is maintained to reflect current developments while preserving historical context for longitudinal analysis of the company's progress.
Rigel Pharmaceuticals presented three studies at the 2024 ASCO Annual Meeting highlighting the long-term efficacy of REZLIDHIA® (olutasidenib) in treating relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML). The Phase 2 trial showed a 35% complete remission or partial hematologic recovery rate among 147 patients, while elderly patients (aged 75+) achieved a 31% CR/CRh rate. Additionally, Rigel presented the Phase 1b trial of R289, an IRAK1/4 inhibitor, in lower-risk myelodysplastic syndrome (LR-MDS). The studies suggest durable responses and tolerability of olutasidenib, even in difficult-to-treat cases.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that its president and CEO, Raul Rodriguez, will present a company overview at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:30 am ET in New York, NY.
The presentation will be available via live webcast on Rigel's Investor Relations website.
Founded in 1996 and based in South San Francisco, Rigel focuses on developing therapies for hematologic disorders and cancer. For more information, visit www.rigel.com.
Rigel Pharmaceuticals announces significant presentations at the upcoming 2024 ASCO and EHA Hybrid Congresses, showcasing the efficacy of their lead products, REZLIDHIA (olutasidenib) for mIDH1 AML and TAVALISSE (fostamatinib) for chronic immune thrombocytopenia (ITP).
The final five-year results from the Phase 2 trial highlight REZLIDHIA's durable responses in heavily pretreated mIDH1 AML patients. Further, REZLIDHIA proves effective in elderly, transplant-eligible, and post-MPN patients.
Additionally, data from a Phase 1b trial of R2891, an IRAK1/4 inhibitor for lower-risk myelodysplastic syndrome (LR-MDS), and real-world analyses of TAVALISSE for ITP will be presented.
These results underscore Rigel's robust hematology and oncology portfolio, promising significant benefits for patients with challenging conditions.
Rigel Pharmaceuticals, Inc. reported total revenue of $29.5 million for the first quarter of 2024, driven by strong commercial demand for TAVALISSE® and REZLIDHIA®. The company acquired GAVRETO®, a U.S. marketed product for lung and thyroid cancer, expanded its portfolio, and appointed a new Chief Medical Officer. Rigel is progressing clinical trials, collaborating with MD Anderson and CONNECT, and advancing pipeline programs. Financially, total revenue included $21.1 million from TAVALISSE sales, $4.9 million from REZLIDHIA sales, and $3.5 million from collaborations. The net loss was $8.2 million. Rigel had $49.6 million in cash and investments as of March 31, 2024.
Rigel Pharmaceuticals, Inc. will report its first quarter 2024 financial results on May 7, 2024, followed by a conference call and webcast discussing financial results and business updates. Rigel Pharmaceuticals is focused on developing therapies for hematologic disorders and cancer.
FAQ
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
What is the market cap of Rigel Pharmaceuticals (RIGL)?
